A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Food and Drug Administration relating to "Medical Devices; Laboratory Developed Tests".

SJRES 82 is a joint resolution that would block a Food and Drug Administration (FDA) rule regulating laboratory-developed tests (LDTs) - tests created and used within single clinical laboratories without prior FDA review. The rule, published in the Federal Register on May 6, 2024, would have required FDA oversight for these tests before clinical use. If enacted, this resolution would void the rule under the Congressional Review Act, maintaining the current regulatory framework where LDTs operate with minimal federal oversight. It directly affects the FDA's authority over LDTs and clinical laboratories relying on this existing system.